quantbrah

Trading the situation. AI turns X posts into trackable portfolios. Not financial advice.

Lilly’s retatrutide data points to continued obesity-drug leadership and share gains versus current GLP-1 incumbents

The post makes a direct, forward-looking claim that Lilly’s Phase 3 retatrutide results are so strong that the drug will surpass tirzepatide and semaglutide and become the leading obesity therapy. The cleanest market translation is a concentrated long in Eli Lilly, with a smaller short in Novo Nordisk as the most exposed incumbent whose semaglutide franchise risks relative competitive pressure.

ALL TIME RETURN +4.30%
S&P 500 +1.84%
VS S&P 500 +2.46%
Return +1.86%
S&P 500 +0.71%
VS S&P 500 +1.15%
Best performer LLY +3.70%
Portfolio S&P 500 AS OF MAY 29, 10:30 PM
  • LLY Long
    Performance +6.06%
    Current weight 80.50%

    Description Retatrutide Phase 3 success strengthens Lilly’s obesity franchise and future market-share leadership.

  • NVO Short
    Performance -2.77%
    Current weight 19.50%

    Description Semaglutide franchise faces relative share and perception pressure from stronger Lilly data.

Created
Last checked
Positions
2

Not financial advice. Hypothetical portfolio for informational purposes only. Returns are approximate and do not account for splits, dividends, borrow costs, or financing. Privacy notice.